Henry Schein, Inc. (NASDAQ:HSIC) Stock Has Consensus Target Price of $92.93 According to Analysts

Posted by Francis Steltz on Oct 5th, 2026

Henry Schein, Inc. (NASDAQ:HSIC – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $92.93.

HSIC has been the topic of several research reports. BTIG Research lifted their target price on Henry Schein from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, August 19th. Stifel Nicolaus set a $95.00 price target on Henry Schein in a research note on Wednesday, August 5th. Barrington Research set a $104.00 price target on Henry Schein in a report on Wednesday, August 5th. Citigroup reaffirmed a “buy” rating and issued a $112.00 price objective (up from $100.00) on shares of Henry Schein in a research note on Wednesday, August 5th. Finally, Piper Sandler lifted their price objective on Henry Schein from $91.00 to $95.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th.

Get Our Latest Research Report on HSIC

Institutional Investors Weigh In On Henry Schein

Several large investors have recently bought and sold shares of HSIC. Operose Advisors LLC bought a new position in Henry Schein during the second quarter valued at $33,000. Trust Co. of Vermont bought a new stake in shares of Henry Schein in the 2nd quarter worth about $42,000. Versant Capital Management Inc increased its holdings in shares of Henry Schein by 175.4% in the 2nd quarter. Versant Capital Management Inc now owns 617 shares of the company’s stock worth $52,000 after buying an additional 393 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Henry Schein by 167.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 936 shares of the company’s stock valued at $69,000 after buying an additional 586 shares in the last quarter. Finally, Contravisory Investment Management Inc. purchased a new stake in shares of Henry Schein during the 2nd quarter valued at about $84,000. Institutional investors own 96.62% of the company’s stock.

Henry Schein Price Performance

HSIC stock opened at $84.88 on Monday. Henry Schein has a one year low of $61.94 and a one year high of $92.18. The company’s fifty day moving average price is $87.80 and its 200-day moving average price is $81.44. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.73 and a current ratio of 1.32. The company has a market capitalization of $9.46 billion, a PE ratio of 24.75, a price-to-earnings-growth ratio of 1.50 and a beta of 0.84.

Henry Schein (NASDAQ:HSIC – Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, topping analysts’ consensus estimates of $1.24 by $0.03. The firm had revenue of $3.46 billion during the quarter, compared to analyst estimates of $3.37 billion. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. Henry Schein’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.10 earnings per share. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. On average, equities analysts anticipate that Henry Schein will post 5.36 EPS for the current fiscal year.

About Henry Schein

(Get Free Report)

Henry Schein, Inc (NASDAQ: HSIC) is a global provider of health care products and services serving dental and medical professionals, laboratories, health care institutions and veterinary practices. The company operates primarily as a distributor, helping customers obtain medical, dental and veterinary supplies, equipment, pharmaceuticals and related products.

In addition to product distribution, Henry Schein provides technology solutions and value-added services designed to support practice management, clinical workflows, procurement, compliance and business operations.